ISO 10993 biocompatibility evaluation, planned from the risk
Holding a laboratory quote you cannot judge? We build the biological evaluation plan from your materials, chemistry and body contact, so tests match real gaps and waivers rest on evidence.
Biological safety is a risk assessment, not a test checklist
The ISO 10993 series treats biological safety as part of risk management. The current edition of ISO 10993-1 asks you to know your materials, processing and body contact first. Testing then fills the gaps that existing data and chemistry cannot close. Many files still start from a test matrix instead. That approach costs time and animals, and it often leaves reviewers asking why a test was run or skipped.
We start with the device. We map every patient-contacting material, additive, adhesive, colorant and processing aid. We note how molding, cleaning and sterilization might change them. We then categorize the nature and duration of body contact. That identifies the biological endpoints to consider, such as cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity and implantation effects.
For each endpoint we decide what evidence fits best. It may be material history, chemical characterization, a toxicological risk assessment or new biocompatibility testing. The biological evaluation plan records those decisions and the reasoning before work starts. The biological evaluation report later pulls the results together and states the conclusion on residual biological risk.
Our team has a materials and polymer chemistry background. That helps when the question is what a coating, elastomer or hydrogel can release, and how sterilization or aging changes it. It also helps when a supplier will not disclose a full formulation, because we know which analytical data can fill the gap.
What a biocompatibility engagement covers
We prepare the technical evidence and documents. Your accredited test laboratory runs the studies we specify.
Biological evaluation plan
A plan that lists materials, contact category and duration, relevant endpoints, existing data, proposed chemistry and tests, and a justification for each endpoint not tested.
Materials and contact mapping
A component-by-component inventory of patient-contacting materials, additives and processing aids. It records the body contact category and cumulative contact duration for each device configuration and intended use.
Chemical characterization strategy
An extraction and analytical plan aligned with ISO 10993-18. It sets solvents, conditions, screening methods, the analytical evaluation threshold, and how unknown compounds will be identified or treated.
Toxicological risk assessment
Compound-by-compound assessment of extractables or leachables against tolerable intake or tolerable contact levels. It reports margins of safety and flags clearly where toxicity data are thin or missing.
Test specification and review
Study specifications for cytotoxicity, sensitization, irritation and any other endpoints still open. We also review laboratory reports critically for sample preparation, extraction conditions, controls and interpretation.
Biological evaluation report
A report that integrates chemistry, toxicology, test results and clinical history into one conclusion on residual biological risk. It is written for your technical file or regulatory submission.
Three stages from inventory to conclusion
Characterize the device
We review drawings, bills of materials, supplier data and manufacturing steps. We confirm the contact category and duration, then identify which biological endpoints need evidence and what data already exist.
Plan the evidence
We draft the biological evaluation plan. Chemistry and toxicology come first where they can answer an endpoint. Biocompatibility testing is specified only where a real gap remains, with sample preparation stated.
Assess and report
We interpret chemistry data and laboratory reports, complete the toxicological risk assessment, and write the biological evaluation report. We stay available for reviewer or notified body questions on the reasoning.
How biocompatibility questions typically arrive
Medical device start-up
A wearable skin patch built on a new adhesive
- Situation
- The team has a wearable sensor patch worn on intact skin for several days. The adhesive is new to them and to the market. A test house has quoted a long list of studies. The team wants to know which are needed and which can be justified away.
- How we advise
- We would map each layer that touches skin and set the contact category, counting repeated wear. Cytotoxicity, sensitization and irritation are the usual starting endpoints for skin contact, and the plan would confirm whether wear duration adds others. We would plan extractables work on the adhesive, because residual monomers and additives can drive sensitization. A toxicological risk assessment would then frame testing and support rationales for endpoints not tested.
- What you receive
- A biological evaluation plan, an extraction and analytical study outline, a test specification for the endpoints that need testing, and the rationale text for each waived endpoint.
Cosmetic brand
Substantiating cosmetic safety without device-style testing
- Situation
- A brand is launching a leave-on serum with two newer actives. Retail partners and regulators expect documented safety substantiation. The team is unsure whether device-style biocompatibility testing applies, or what evidence a safety assessment needs.
- How we advise
- We would explain that cosmetic safety rests on ingredient toxicology and exposure, not on ISO 10993 tests. We would gather hazard data for each ingredient and impurity of concern. We would then estimate systemic exposure from realistic use amounts, calculate margins of safety and review local effects such as irritation and sensitization. Where data are missing, we would flag the gap and propose the least burdensome way to close it.
- What you receive
- An ingredient toxicology dossier with exposure calculations and margins of safety, ready for the responsible safety assessor, such as the qualified safety assessor required in the EU.
Device manufacturer
A supplier changes a colorant in a marketed device
- Situation
- A resin supplier has replaced the pigment in a colored housing that contacts skin. The material grade name is unchanged. Quality wants to know whether the existing biological evaluation still holds, or whether biocompatibility testing must be repeated.
- How we advise
- We would compare old and new formulations using supplier disclosures and, where needed, comparative extractables data. If the chemical profile is equivalent, the existing evidence can usually be carried forward with a documented rationale. If new compounds appear, we would assess them toxicologically. Testing would be proposed only for endpoints the chemistry and toxicology cannot address.
- What you receive
- A change assessment memo with the comparison data, a toxicological review of any new constituents, and an updated section for the biological evaluation report.
Illustrative scenarios. Each is a composite of common client situations, not a specific engagement.
Start with a defined piece of work
Frequently asked questions
Do you run biocompatibility testing in-house?
No. We design the evaluation, write the study specifications and review the results. Testing is done by an accredited laboratory you select, often working to GLP. We can help you compare lab proposals and check that extraction conditions match the plan. Separating design from testing gives you an independent view of each study.
What do you need from us to start a biological evaluation plan?
We need a device description and intended use, drawings or a bill of materials, and supplier information for every patient-contacting part. Manufacturing and sterilization details matter, because processing changes what can leach. Existing test reports, chemistry data or clinical history also help. We will tell you which supplier disclosure gaps matter.
Can chemical characterization replace animal testing?
Sometimes, for some endpoints. The risk-based approach expects you to use existing data and chemistry before new testing. A sound chemical characterization study with a toxicological risk assessment can often address systemic toxicity endpoints. Sensitization or implantation effects may still need testing. The answer depends on the device, the contact and the data quality.
Which regulators accept this approach?
The FDA recognizes many parts of the ISO 10993 series as consensus standards, some only in part, and publishes its own guidance on applying ISO 10993-1. In the EU, the series is widely used to show conformity with MDR safety requirements. Recognition of a new edition can be partial or delayed, so we check current status for your market. Acceptance rests with the reviewer, so we document the reasoning rather than promise an outcome.
How long does a biological evaluation take?
The plan depends on how complete your materials and supplier data are. Most of the total timeline is laboratory work, which can run for months for long-term implants. The main drivers are the number of materials, supplier disclosure gaps, and whether chemistry raises compounds that need toxicological follow-up. We give a timeline after scoping.
When does a change require a new biological evaluation?
Any change to materials, suppliers, formulation, processing, sterilization or packaging should trigger a review. Many changes can be closed with a documented rationale and comparison data. Others need new chemistry or tests. The key is to record the assessment, because reviewers will ask how each change was considered.
Plan your biological evaluation with us
Share your device description and materials list. We’ll follow up by email and send a written quote for reviewing the endpoints and the evidence needed.
Neucite Consulting prepares technical evidence and documents for biological evaluation; conformity decisions rest with regulators and notified bodies, and testing is performed by independent laboratories.